Feedback / Questions
efdamrofusp alfa (IBI-302) - Innovent Biologics
https://www.prnewswire.com/news-releases/innovent-announces-oral-presentation-of-full-phase-2-clinical-data-for-efdamrofusp-alfa-ibi302-first-in-class-anti-vegfcomplement-bispecific-fusion-protein-at-arvo-2025-302445964.html
May 5, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next